Keywords
Hepatocellular carcinoma · Hepatitis B virus · Immune-tolerant phase · Nucleos(t)ide analogs · Alanine aminotransferase

Abstract
Background: Long-term therapy with nucleos(t)ide analogs (NAs) such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF) favorably affects the incidence of hepatocellular carcinoma (HCC) on the basis of data from randomized or matched control studies. Recent data suggest a lower HCC incidence after 5 years of ETV or TDF therapy in chronic hepatitis B (CHB) patients, especially those with baseline cirrhosis. Summary: Three controversial issues remain to be resolved regarding hepatitis B virus (HBV) treatment and HCC. (1) The efficacy of antiviral treatment for the prevention of HCC is not established. The guidelines of the American Association for the Study of Liver Diseases (AASLD), the Asian Pacific Association for the Study of the Liver (APASL), and the European Association for the Study of the Liver (EASL) for the management of HBV infection state that antiviral treatment of HBV with interferon and NAs prevents the development of HCC. Among experts in CHB treatment, however, there is disagreement on the HCC prevention effects of antiviral treatment. (2) The rationale for antiviral management in patients with high HBV DNA and normal levels of alanine aminotransferase is unclear. The AASLD, EASL, and APASL guidelines do not recommend antiviral treatment for immune-tolerant CHB patients, and the terms and methods of treating such patients remain to be clarified. (3) The efficacy of first-line treatment with NAs, including ETV, TDF, and tenofovir alafenamide fumarate (TAF), to prevent HCC in CHB patients remains unknown. Several studies have produced controversial results regarding the effects of NAs on the risk and prevention of HCC. In the present review, we discuss these 3 issues, citing recent studies and clinical management guidelines from major international associations. Key Messages: Suggested approaches for reaching a consensus including applying the propensity score matching method, performing randomized controlled studies, and performing clinical studies with larger numbers of subjects and longer follow-up.
Introduction

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) and the second leading cause of cancer-related mortality worldwide [1, 2]. Global deaths from HCC attributed to hepatitis B virus (HBV) are projected to double by 2040 [1–3]. Analysis of randomized or matched control studies indicates that long-term therapy with nucleos(t)ide analogs (NAs), such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF), reduces the incidence of HCC [4–6].

Recent data suggest that 5 years of ETV or TDF therapy reduces the incidence of HCC in CHB patients, especially those with baseline cirrhosis [4, 6]. Nonetheless, the following 3 controversial issues regarding HBV treatment and the incidence of HCC remain to be resolved.

1. The efficacy of antiviral treatment for the prevention of HCC is not established.

Guidelines of the American Association for the Study of Liver Diseases (AASLD) [7], the Asian Pacific Association for the Study of the Liver (APASL) [8], and the European Association for the Study of the Liver (EASL) [4] for the management of HBV infection recommend antiviral treatment for HBV with interferon (IFN) and NAs for the prevention of HCC. Among experts in CHB treatment, however, there is disagreement on the HCC prevention effects of antiviral treatment.

2. The rationale for antiviral treatment of patients harboring high HBV DNA and normal alanine aminotransferase levels is not yet clear.

AASLD, EASL, and APASL guidelines have not reached a consensus regarding the efficacy of treatment during the immune-tolerant phase. Although positive hepatitis B e antigen (HBeAg), high serum HBV DNA, and normal alanine aminotransferase (ALT) levels are 3 key features of this phase, the guidelines do not currently recommend antiviral treatment for immune-tolerant CHB patients.

Further, the correlation between very high HBV DNA levels (especially >6 log_{10} IU/mL) and risk of HCC remains unclear, especially in middle-aged and older HBeAg-positive patients with normal ALT levels [1, 9]. Thus, the terms and methods of treating CHB patients with high levels of HBV DNA and normal levels of ALT in the immune-tolerant phase must be clarified.

3. The efficacy of first-line NAs, including ETV, TDF, and tenofovir alafenamide fumarate, for CHB patients to prevent HCC remains unclear.

ETV, TDF, and tenofovir alafenamide fumarate (TAF) in the AASLD and EASL clinical practice guidelines [4, 7], and ETV and TDF in the APASL clinical practice guidelines are recommended as first-line NAs for CHB because of their comparable high antiviral efficacy and low rate of resistance [8]. The results of several studies of ETV, TDF and TAF administration, however, have raised questions regarding the risk of HCC. To date, no studies have provided clear evidence regarding the potential HCC prevention effects of ETV, TDF, and TAF administration [10–16]. In the present review, we address these 3 issues and cite recent studies on HBV treatment and HCC prevention with reference to AASLD, EASL, and APASL guidelines for the management of HBV infection and suggest approaches for reaching a consensus.

Efficacy of Antiviral Treatment for HCC Prevention

Regarding the efficacy of antiviral treatment for HBV with IFN and NAs, the AASLD 2018 guidelines for the management of HBV infection state that, as for any patient with CHB, the treatment goals are to reduce the risk of progression to cirrhosis- and liver-related complications, including HCC. The APASL 2016 guidelines for the management of HBV infection state that the risk of CHB progressing to HCC may be reduced by antiviral therapy and recommend liver biopsy for noncirrhotic patients with a family history of HCC as well as treatment for moderate to severe inflammation or significant fibrosis.

The EASL guidelines for the management of HBV infection recommend treatment with NAs for the prevention of HCC in CHB patients [4, 6] on the basis of a European study (Table 1). A European 10-center cohort study of 1,951 adult Caucasian CHB patients (cirrhosis 201, 27%) without HCC at baseline received ETV/TDF for ≥1 year; 1,205 (62%) patients without HCC within the first 5 years of therapy were followed up for 5–10 (median, 6.8) years. HCC was diagnosed in 101/1,951 (5.2%) patients within the first 5 years of therapy were followed up for 5–10 (median, 6.8) years. HCC was diagnosed in 101/1,951 (5.2%) patients within the first 5 years and 17/1,205 (1.4%) patients within 5–10 years, demonstrating that the HCC risk decreases with ETV/TDF therapy beyond year 5, particularly in those with compensated cirrhosis, older age (especially ≥50 years), lower platelet counts, and liver stiffness ≥12 kPa [6] (Table 2).

The AASLD [17], EASL [18], and APASL [19] guidelines for the management of HCC all recommend antiviral therapy for HBV patients to reduce the risk of HCC. Among experts in the treatment of CHB, however, there
is controversy regarding antiviral HBV treatment for the prevention of HCC.

The achievement of HBsAg seroclearance during NA treatment is closely associated with improved clinical outcomes and is a criterion for the safe discontinuation of therapy [20]. HBsAg seroclearance is rarely, if ever, achievable, however, and necessitates long-term (almost indefinite) NA therapy for most patients with CHB. In the absence of HBsAg seroclearance, HCC can occur even during long-term continuous treatment with highly potent NAs [21–24].

A virologic response is defined as serum HBV DNA <15 IU/mL at 1 year of treatment for CHB or the achievement of a sustained virologic response for chronic hepatitis C (CHC). Kim et al. [23] reported that a virologic response was achieved in 1,520 patients with CHB (76.0%) and 475 patients with CHC (64.8%). During the median follow-up period of 6 years, 228 patients with CHB (11.4%) and 59 patients with CHC (8.0%) developed HCC. Among patients with virologic response, CHB was independently associated with a significantly higher incidence of HCC (hazard ratio [HR] 2.17; 95% confidence interval [CI] 1.30–3.63; \( p = 0.003 \)) compared with CHC.

This does not mean cure, however, and does not address the reason for the persistent risk of HCC in CHB patients with a virologic response [23]. A positive outcome of antiviral treatment with NAs for the prevention of HCC was described in 651 randomly assigned patients having CHB with histologically confirmed cirrhosis or advanced fibrosis (98% Asian and 85% male) receiving lamivudine (LAM) or placebo. HCC occurred in 3.9% of the LAM group (\( n = 436 \)) and 7.4% of the placebo group (\( n = 215 \); \( p = 0.047 \); Table 2) [25].

A comparison between 482 ETV-treated and 69 untreated (control group) HBV-related cirrhosis patients (total of 551) revealed that ETV treatment reduced the risk of HCC (propensity score matching: HR 0.55, 95% CI: 0.31–0.99, \( p = 0.049 \); Table 2) [26]. In a comparison of the incidence of HCC in 472 ETV-treated (cirrhosis 311, 19.2%) and 1,143 untreated HBV patients (cirrhosis 195, 12.1%), propensity score matching eliminated baseline differences, resulting in a sample size of 316 patients per cohort. The cumulative HCC incidence rate at 5 years was 3.7% and 13.7% in the ETV and control groups, respectively (\( p < 0.001 \)). Cox proportional hazard regression analysis adjusted for a number of known HCC risk factors showed that patients in the ETV group were less likely to develop HCC than those in the control group (HR 0.37, 95% CI: 0.15–0.91, \( p < 0.001 \); Table 2), leading to the conclusion that long-

---

**Table 1. Comparison of major international guidelines for the management of HBV**

| AASLD, 2018 | EASL, 2017 | APASL, 2015 |
|-------------|------------|------------|
| **1 Prevention of HCC with IFN and NAs in HBV** | Pos | Pos | Pos |
| **2 Definition of immune-tolerant phase** | ALT <35 U/L in men, <19 U/L in women, HBeAg (+), HBV DNA >106 IU/mL | ALT <30 U/L in men, <19 U/L in women, HBeAg (+), Chronic HBV infection | Not recommended |
| **3 Antiviral treatment for immune-tolerant phase** | Not recommended | Not recommended | Not recommended |
| **4 First-line treatment for CHB** | ETV, TDF, and TAF | ETV, TDF, and TAF | ETV, TDF, and TAF |

**AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; APASL, Asian Pacific Association for the Study of the Liver; HCC, hepatocellular carcinoma; IFN, interferon; NAs, nucleos(t)ide analogs; HBV, hepatitis B virus; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; CHB, chronic hepatitis B; ETV, entecavir; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide fumarate.**
| Author/year             | Cirrhosis patients’ population | NAs                          | Outcome                                                                 | Prevention of HCC under NAs positive or suspected |
|------------------------|-------------------------------|------------------------------|-------------------------------------------------------------------------|--------------------------------------------------|
| Liaw et al. [25] 2004  | Cirrhosis or advanced fibrosis, LAM-treated: 436; placebo group: 215 | LAM                          | HCC in 3.9% patients in LAM group (n = 436) and 7.4% of those in placebo group (n = 215) (HR 0.49, p = 0.047) | Positive                                         |
| Wong et al. [26] 2013  | Cirrhosis, ETV-treated: 482; control group: 69                          | ETV                          | ETV-treated patients (n = 482) showed reduced risk of HCC compared with controls (n = 69). (HR 0.55, 95% CI: 0.31–0.99, p = 0.049) | Positive                                         |
| Hosaka et al. [27] 2013| Cirrhosis, ETV-treated: 116 (25%); control group: 195 (17%)             | ETV                          | The cumulative HCC incidence rates at 5 years 3.7% and 13.7% in ETV (n = 472) and control group (n = 1143), respectively (p < 0.001) | Positive                                         |
| Wu et al. [28] 2014    | Cirrhosis, NAs-treated: 2,847 (13.2%); controls: 3,016 (14.0%)           | ETV, LAM, and telbivudine    | The NAs-treated cohort (n = 21,595) showed a significantly lower 7-year incidence of HCC (7.32%; 95% CI: 6.77–7.87%) than controls (n = 21,595) (22.7%; 95% CI: 22.1–23.3%; p < 0.001) | Positive                                         |
| Papatheodoridis et al. [6] 2017 | Cirrhosis, ETV/TDF-treated: 201                                   | ETV and TDF                  | HCCs diagnosed in 101/1,951 (5.2%) patients within first 5 years and 17/1,205 (1.4%) patients within 5–10 years in Caucasian CHB patients | Positive                                         |
| Sut et al. [29] 2016   | Cirrhosis, ETV-treated: 1,315; untreated group: 503                       | ETV                          | Compared with the untreated cohort (n = 503), treated patients (n = 1,315) were associated with a 60% HCC risk reduction (HR 0.40, 95% CI: 0.28–0.57) | Positive                                         |
| Choi et al. [21] 2017  | Population-based cohort No description regarding the percentage of cirrhosis | LAM, ADV, telbivudine, clevudine, ETV, and TAF | Annual deaths from liver cancer increased by 17.8% (95% CI: 17.6–18.0), while the annual number of patients receiving oral antiviral agents against HBV increased from 1,716 to 187,226 between 1999 and 2013 | Suspected                                         |

HCC, hepatocellular carcinoma; NAs, nucleos(t)ide analogs; LAM, lamivudine; ETV, entecavir; TDF, tenofovir disoproxil fumarate; ADV, adefovir; HR, hazard ratio; CI, confidence interval.
term ETV treatment reduces the incidence of HCC in HBV-infected patients [27].

A comparison by propensity score matching between 21,595 ETV-treated (cirrhosis 2,847, 13.2%) and 21,595 untreated CHB patients (cirrhosis 3,016, 14.0%) demonstrated that the incidence of HCC was significantly lower in the treated cohort over a 7-year follow-up (7.32%, 95% CI: 6.77–7.87) than in the control (22.7%, 95% CI: 22.1–23.3, p < 0.001; Table 2) [28]. Another study comparing between 1,315 ETV-treated cirrhosis patients and 503 untreated HBV-related cirrhosis patients concluded that ETV therapy was associated with a 60% lower risk of HCC incidence (HR 0.40, 95% CI: 0.28–0.57; Table 2) [29]. Even with successful treatment using antivirals, the risk of HCC is not eliminated and surveillance for HCC should continue in persons who are at risk.

To evaluate whether NA therapy prevents HCC in HBV patients, a population-based analysis of mortality from liver disease and liver cancer from 1999 to 2013 was implemented using data obtained from the national death certificate database of Korea, an HBV-endemic country. In terms of liver disease, the number of annual deaths decreased by 62.3% (95% CI: 62.0–62.6) and the crude death rate decreased by 64.6% (95% CI: 64.3–64.9) from 21.2 to 7.5 per 100,000 population; the age-standardized death rate also declined by 75.0% (95% CI: 74.7–75.3). In contrast, the number of annual deaths from liver cancer increased by 17.8% (95% CI: 17.6–18.0) and the crude death rate increased by 10.2% (95% CI: 10.0–10.4) from 20.5 to 22.6, although the age-standardized death rate decreased by 26.9% (95% CI: 26.6–27.2). The annual number of patients receiving oral antiviral agents against HBV increased from 1,716 to 187,226 during the study period [21] (Table 2).

The age-standardized mortality rate of liver cancer and incidence rate greatly decreased from 24.7 and 33.8, respectively, in 1999, to 16.4 and 19.9, respectively, in 2014. The dissociation between crude rates and age-standardized rates for liver cancer mortality and incidence may be explained by the rapidly aging population in Korea. The crude rates and absolute number of liver cancer mortality and incidence rates continue to increase. These data suggest that liver cancer is currently the most important cancer to overcome in Korea [30].

Previous studies reported a dissociation between trends in total death (increased) and age-standardized death rate (decreased) in the global burden of the disease [31]. These findings were attributed to changes in population growth and shifts in global age structures. In addition, the competing nature between liver disease mortality and liver cancer mortality should be carefully considered [21]. For example, in terms of the absolute death number, the wide use of antiviral drugs for hepatitis B and C may cause a rapid decline in liver disease mortality. Expanding the number of the at-risk population, however, may inadvertently lead to an increase in the absolute liver cancer incidence and mortality.

To observe prevention of HCC, a randomized controlled trial involving patients given ETV, TDF, or TAF and untreated patients would not be realistic. To reach a consensus, a comparison should be conducted between the incidence of HCC in ETV- or TDF-treated and untreated HBV patients (control group) using the propensity-scored matching method adjusted for a number of HCC risk factors, as described previously [26, 27] (Table 2).

Rational for Antiviral Treatment of Patients Harboring High HBV DNA and Normal ALT Levels

The immune-tolerant phase, representing the early phase of the CHB, is not well understood. The concept of true immune-tolerance has been underestimated from the viewpoint of immunology and major international guidelines from AASLD, EASL, and APASL have not yet reached a consensus on the definition of the immune-tolerant phase [32]. While positive HBeAg, high serum HBV DNA levels, and normal serum ALT levels are the 3 key features of this phase, the APASL guidelines also take age into consideration [8] (Table 1). No consensus has been reached, however, regarding the lower cutoff level of HBV DNA for defining the immune-tolerant phase, which varies between 6 log10 IU/mL and 2 × 7 log10 IU/mL in clinical practice guidelines [4, 7, 8, 33]. A new nomenclature, Phase 1 or HBeAg-positive chronic HBV infection, is given by the latest version of the EASL guidelines published in April 2017 [4]. Although current major international guidelines advise against starting antiviral treatment for immune-tolerant CHB patients [4, 7, 8] (Table 1), some new data suggest that treating such patients may reduce the risk of liver fibrosis and the progression to HCC.

Current practice guidelines recommend delaying therapy until patients show significantly increased ALT levels or evidence of inflammation and/or fibrosis on biopsy [4, 7, 8, 33] (Table 1). These recommendations are based on the notion that disease progression to hepatic fibrosis and cirrhosis begins with an immune-active phase.
In a natural cohort study of CHB patients (REVEAL-HBV study), the HCC risk was highest at HBV titers >10^6 copies/mL (~5 log_{10} IU/mL) regardless of serum ALT levels or HBeAg [34]. In previous studies, patients with HBV DNA levels at 10^6–10^7 copies/mL had a significantly higher risk of HCC compared with those having persistent HBV DNA levels >10^7 copies/mL or <10^6 copies/mL [34].

A cohort study in Korea was conducted with 6,949 noncirrhotic, treatment-naïve CHB patients (mean age 45 years) having ALT levels <2 times the upper limit of normal for 1 year. During 8.0 years of median follow-up, 363 patients (5.2%) developed HCC. By multivariate Cox regression analysis, the HCC risk was highest with a baseline HBV DNA level of 6–7 log_{10} IU/mL (HR 4.98, \( p < 0.001 \)) and lowest with a baseline HBV DNA level of >8 log_{10} IU/mL (HR 0.90, \( p = 0.71 \)) and ≤4 log_{10} IU/mL (HR 1.00, reference), independent of other predictive factors. The HCC risk was highest with a moderate serum HBV DNA level of 6–7 log_{10} IU/mL in CHB patients without significant ALT elevation [1].

Untreated patients in the immune-tolerant phase have a significantly higher risk of HCC than immune-active phase patients treated with NAs [9]. The presence of significant hepatic necroinflammation/fibrosis is a significant risk factor for HCC and liver disease progression. Few patients, however, undergo repeat liver biopsy because of its invasive nature. The use of noninvasive tests for hepatic fibrosis is also limited because of their inaccuracy in identifying a significant fibrosis (i.e., F2 fibrosis). Those with a positive family history of HCC and African ethnicity may harbor a greater risk of HCC [17–19].

Untreated HBeAg-negative CHB patients with a high viral load but no significant increase in ALT levels display a higher risk of clinical events than treated patients in an active phase with elevated ALT [35]. The relation between the occurrence of HCC and high HBV DNA levels without ALT elevation is viewed as follows.

Selection and expansion of clonal hepatocytes are major risk factors for HCC and are observed without increased ALT levels or hepatic fibrosis [36–39]. Therefore, reduction of HBV DNA levels to <8 log_{10} IU/mL, despite its persistence at >4 log_{10} IU/mL in HBeAg-positive CHB patients, suggests clonal hepatocyte expansion and an increased risk of HCC, even with persistently normal ALT levels. HBV DNA integration into human host chromosomes may further increase chromosomal instability [36].

Progressive integration of the HBV genome into human host chromosomes may increase serum HBV DNA levels to >4 log_{10} IU/mL in HBeAg-negative patients [40, 41]. A recent study demonstrated that increasing levels of viremia above 20,000 IU/mL indicate a higher frequency of HBV-host genome integration in HBeAg-negative patients currently not indicated for treatment [40]. Random integration of the viral genome into host chromosomes may result in the loss of tumor suppressor gene functions, and/or the activation of tumor-promoting genes that are specifically involved in hepatocarcinogenesis [38, 40].

A recent study demonstrated that inhibition of HBV replication by TDF reduces the number of transcriptionally active distinct HBV-host DNA integrations in patients with HBV viremia above 2,000 IU/mL and minimally elevated ALT levels [42]. Thus, the findings mentioned above [35] may explain the high HCC risk in individuals with increased HBV DNA levels (>4 log_{10} IU/mL) among HBeAg-negative CHB patients. It is well known that HBV-associated hepatocarcinogenesis occurs without signs of significant hepatic inflammation and/or fibrosis [35].

Several studies have consistently shown that the application of current guideline recommendations may be too late to considerably prevent HCC, although the progression of fibrosis may be blocked [9, 21, 35]. If the goal of antiviral treatment is more the prevention of HCC than the prevention of hepatic inflammation and/or fibrosis progression, the recommendations may have to be considered with caution [43].

Early treatment intervention should therefore be considered to prevent HCC before ALT levels increase in patients with moderate viral loads of between 4 and 8 log_{10} IU/mL, especially those older than 40 years of age. Accumulating data on the long-term efficacy and safety of ant-HBV drugs such as ETV, TDF, and TAF offer a potent high genetic barrier to resistance, and decreasing their cost may facilitate initiation of early treatment [44–46]. With these considerations in mind, recent findings may help provide appropriate treatment options to obviate HCC in CHB patients [1].

Given the poor prognosis of patients with HCC, these findings may have considerable clinical implications toward preventing cancer in patients with CHB. Current treatment guidelines for CHB should be interpreted with caution given that HBV-associated hepatocarcinogenesis could be underway in patients who are not eligible for antiviral therapies by current guidelines. Therefore, efforts to reconcile treatment guidelines with recent clinical evidence should be made to further reduce the development of HCC [47].
Additional studies are needed to refine HCC risk prediction models by incorporating a broad range of HBV DNA levels. Randomized controlled trials based on those accurate models may be warranted to determine whether antiviral treatment reduces the risk of HCC in noncirrhotic CHB patients with moderate levels of HBV DNA and no significant ALT increase [1].

Efficacy of First-Line Treatment with NAs, ETV, TDF, and TAF, for CHB to Prevent HCC

ETV, TDF, and TAF in the AASLD and EASL guidelines, and ETV and TDF in the APASL guidelines are equally recommended as first-line NAs for CHB in clinical settings because of their similarly high antiviral efficacy and low rate of resistance [4,7,8] (Table 1). Regarding the reduction of HCC with NAs such as ETV and TDF, however, the results are controversial and inconsistent in a number of studies demonstrating more favorable outcomes with TDF than with ETV treatment. A study comparing ETV and TAF showed no difference between the 2 groups in reducing the HCC risk [48]. Another recent real-world data study indicates that TAF has comparable efficacies to TDF in terms of the risk of HCC [49].

In Korea, one of the most HB-endemic nations, a nationwide cohort study, validated by a hospital cohort for the first time demonstrated that CHB patients treated with TDF were at significantly lower risk of developing HCC than those treated with ETV [24]. In the national cohort, the annual incidence rate of HCC was significantly lower in the TDF group \(n=12,692\), 0.89 per 100 PY \(p<0.01\) than in the ETV group \(n=11,464\), 1.19 per 100 PY. By multivariate-adjusted analysis, TDF therapy was associated with a significantly lower risk of HCC (HR 0.68, 95% CI: 0.59–0.77). Compared with the ETV group \(n=1,560\), the TDF group also showed a significantly lower risk of HCC in the 10,923-pair propensity score-matched national cohort (HR 0.68, 95% CI: 0.60–0.78) and 869-pair propensity score-matched hospital cohort (HR 0.68, 95% CI: 0.46–0.99, Table 3) [24].

Furthermore, HCC recurrence was compared between patients treated with TDF or ETV after surgical resection of HBV-related HCC. A cohort study conducted between 2010 and 2018 included 1,695 consecutive patients treated with ETV \(n=813\) or TDF \(n=882\) after curative-intent hepatectomy for HBV-related HCC of Barcelona Clinic Liver Cancer stage 0 or A. Posthepatectomy, HCC recurrence and overall survival were compared between the ETV- and TDF-treated groups by propensity score matching and multivariate-adjusted Cox regression analyses (Tables 4, 5).

During the median follow-up of 37.6 months with continued ETV or TDF therapy, HCC recurred in 561 (33.1%) patients. By multivariate-adjusted analysis, the TDF group demonstrated significantly lower rates of HCC recurrence (HR 0.82; 95% CI: 0.68–0.98; \(p=0.03\)) and death or transplantation (HR 0.62; 95% CI: 0.44–0.88; \(p=0.01\); Table 3) [10].

The mechanisms of TDF and ETV, with the former imparting a significantly lower risk of HCC than the latter, might be explained, in part, by the better virologic response profiles of the TDF group, as shown in the hospital cohort, and in other studies [50–52]. Nevertheless, considering that a virologic response is not an independent risk factor for HCC, the difference in the HCC risk after TDF or ETV treatment cannot be fully explained by their antiviral potency. A recent study demonstrated that higher serum IFN-λ3 levels are induced in patients treated with the nucleotide analogs adefovir dipivoxil and TDF, but not in those treated with the nucleoside analogs LAM and ETV [53]. IFN-λ exhibits potent antitumor activity in murine models of cancer, including hepatoma [54,55]; this antitumor activity is assumed to contribute to the difference in the HCC risk. Moreover, ETV is carcinogenic in mice and rats when administered at doses higher than those used in humans [24]. Also, ETV is known to potentially incorporate into the human genome and to contribute to a putative mechanism of carcinogenicity, especially when the embedded genome has higher error rates during subsequent rounds of replication [56–58]. These data raise concerns about the carcinogenic potential of ETV, even at clinical doses during long-term treatment, especially in patients with cirrhosis and increased chromosomal instability of hepatocytes [59,60].

Several reports from Korea, however, have questioned the conclusions reached in other studies. A total of 7,015 consecutive patients diagnosed with CHB were treated with TDF or ETV between February 2007 and January 2018 at the liver unit of the Catholic University of Korea and screened for study eligibility; finally, 3,022 patients (ETV: 1,583, TDF: 1,439) were analyzed. No difference in the incidence rate of HCC between TDF and ETV therapy was detected in the entire cohort (HR 1.030, 95% CI: 0.703–1.509, \(p=0.88\); Table 3) or in subgroups with chronic hepatitis and cirrhosis [15].

In a study of 404 CHB patients (ETV \(n=180\), TDF \(n=224\)), TDF was associated with a lower incidence of HCC (HR 0.31, 95% CI: 0.12–0.79; \(p=0.014\)), but no statistical significance was detected after adjusting for sus-
### Table 3. Comparison of ETV, TDF, and TAF on reduction of HCC

| Study area              | Patients | Outcome | Superiority or equality | Reference                  | Year |
|-------------------------|----------|---------|-------------------------|----------------------------|------|
| Korea                   |          |         |                         |                            |      |
| National Cohort         | ETV: 11,464, TDF: 12,692 | ETV: 1.19/100 PY, TDF: 0.89/100 PY | TDF > ETV                | Choi et al. [24]           | 2019 |
| Hospital Cohort         | ETV: 1,560, TDF: 1,141 | HR 0.68, 95% CI: 0.60–0.78, HR 0.68, 95% CI: 0.46–0.99 |                         |                            |      |
| Korea                   | ETV: 1,484, TDF: 1,413 | ETV: 1.92/100 PY, TDF: 1.69/100 PY, HR 0.975, p = 0.852 | ETV = TDF                | Kim et al. [16]            | 2019 |
| Korea                   | ETV: 1,583, TDF: 1,439 | HR 1.030, 95% CI: 0.703–1.509 p = 0.880 | TDF = ETV                | Lee et al. [15]            | 2020 |
| Korea                   | ETV: 180, TDF: 224 | HR 0.36, 95% CI: 0.12–1.14 p = 0.08 | TDF = TDF                | Ha et al. [61]             | 2020 |
| Korea                   | ETV: 813, TDF: 882 | HR 0.82, 95% CI: 0.68–0.98 p = 0.03 (after surgical resection) | TDF > ETV                | Choi et al. [10]           | 2021 |
| Korea                   | ETV: 1,525, TAF: 286 | ETV: 1.67/100 PY, TAF: 1.19/100 PY, HR 0.681, 95% CI: 0.351–1.320, p = 0.255 ETV = TAF | Lee et al. [48]          | 2021 |
| Korea                   | TDF: 2,245, TAF: 502 | TDF: 0.90/100 PY, TAF: 0.82/100PY, p = 0.60 | TDF = TAF                | Lim et al. [49]            | 2022 |
| China                   | ETV: 2,124, TDF: 1,574 | RR 0.66, 95% CI: 0.49–0.89, p = 0.008 | TDF > ETV                | Zhang et al. [12]          | 2019 |
| China                   | ETV: 28,041, TDF: 1,309 | ETV: 0.49/100 PY, TDF: 0.06/100 PY, HR 0.36, 95% CI: 0.16–0.80, p = 0.013 | TDF > ETV                | Yip et al. [11]            | 2020 |
| Taiwan and Asia-Pacific | ETV: 4,837, TDF: 700 | HR 0.89, 95% CI: 0.41–1.92, p = 0.77 | TDF = ETV                | Hsu et al. [14]            | 2020 |
| Taiwan and Asia-Pacific | ETV: 19,702, TDF: 16,266 | ETV: 3.44%/5Y, TDF: 3.39%/5Y, HR 0.88, 95% CI: 0.73–1.07 p = 0.20 | TDF = ETV                | Tseng et al. [71]          | 2020 |
| Hong Kong and China     | ETV: 56,346, TDF: 28,662 | HR 0.73, 95% CI: 0.62–0.85 p < 0.001 | TDF > ETV                | Cheung et al. [70]         | 2020 |
| Europe                  | ETV: 772, TDF: 1,163 | ETV: 1.08/100 PY, TDF: 1.2/100 PY, p = 0.321 | TDF = ETV                | Papatheodoridis et al. [72] | 2020 |
| USA                     | ETV: 2,193, TDF: 1,094 | HR 1.00, 95% CI: 0.76–1.32 | ETV = TDF                | Su et al. [73]             | 2021 |

ETV, entecavir; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide fumarate; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; PY, person-years; RR, rate ratio – HR combined with incidence rate ratios; Y, year.
tained virologic suppression through propensity score matching (HR 0.36, 95% CI: 0.12–1.14; \( p = 0.08 \); Table 3) [61]. Regarding the mechanism underlying the equivalent effects of ETV and TDF on the reduction of HCC, a Korean study observed that the hypothesis of the induction of IFN-\( \lambda \)-3 production by TDF and the carcinogenic potential of ETV is problematic [48].

First, the level of serum IFN-\( \lambda \)-3 imparts higher anticarcinogenic and antiviral effects to patients treated with TDF than to those treated with ETV, but conflicting data are also reported [17, 62–65]. Moreover, because IFN-\( \lambda \) assays are not standardized, the causality of the relation between higher IFN-\( \lambda \)-3 levels and a lower incidence of HCC requires further investigation.

Second, in mice, ETV at 4 mg/kg increases the incidence of lung adenoma and carcinoma, HCC, and vascular tumors, and at 1.4–2.6 mg/kg increases the incidence of HCC, brain microglial tumors, and skin fibroma [66]. These doses, however, are at least 100-fold higher than those used in humans. In contrast, 2 recent large-scale real-life studies demonstrated that long-term ETV therapy does not increase the risk of cancer [67, 68]. Moreover, in a long-term follow-up study [69], the incidence of HCC did not differ statistically during or after the first 5 years of ETV treatment (2.29% vs. 1.66%, \( p = 0.22 \)); should long-term ETV administration induce a significant procarcinogenic effect in humans, the HCC incidence would progress rapidly over time.

A recent Korean study comparing the impact of ETV and TAF on the reduction of HCC [48] demonstrated no statistical difference in the annual incidence of HCC in ETV (\( n = 1,525 \)) and TAF (\( n = 286 \)) patients (1.67 vs. 1.19 per 100 PY, respectively) with HR 0.681, 95% CI: 0.351–1.320, \( p = 0.255 \), as determined by propensity score matching methods, suggesting that ETV- and TAF-treated CHB patients face a similar risk of developing HCC [48]. Studies from China, Taiwan, and Hong Kong as well as from Korea report conflicting results regarding the efficacy of ETV and TDF for obviating HCC [11, 14–16, 24].

In a large nationwide cohort study in Hong Kong, 29,350 treatment-naive CHB patients were started on ETV (\( n = 28,041 \)) and TDF (\( n = 1,309 \)) as first-line therapy. After propensity score weighting and 1:5 matching, TDF was associated with a lower risk of HCC than ETV (HR 0.36, 95% CI: 0.16–0.80, \( p = 0.013 \); Table 3) [11].

In a meta-analysis from Hong Kong, 85,008 CHB patients received ETV (\( n = 56,346 \)) and TDF (\( n = 28,662 \)); TDF was associated with a lower HCC risk than ETV, particularly in cirrhotic patients (HR 0.73, 95% CI: 0.62–

---

**Table 4. Experts’ opinions regarding prevention of HCC with NAs and approaches to solve these controversies**

| Author          | Year | Opinion | Prevention of HCC under NAs positive or suspected |
|-----------------|------|---------|-----------------------------------------------|
| Law et al. [25] | 2004 | Positive| Continuous treatment with lamivudine delays clinical progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis by significantly reducing the incidence of hepatic decompensation and the risk of HCC. |
| Wong et al. [26] | 2013 | Positive| Entecavir therapy reduces the risk of hepatic events, HCC, liver-related, and all-cause mortality in CHB patients, particularly in those with compensated cirrhosis or older age especially ≥50 years, lower platelets, and liver stiffness ≥12 kPa. |
| Hosaka et al. [27] | 2013 | Positive| Long-term ETV treatment may reduce the incidence of HCC in HBV-infected patients. The treatment effect was greater in patients at high risk of HCC. |
| Wei et al. [28] | 2014 | Positive| Nucleoside analog therapy use is associated with reduced risk of HCC in patients with chronic hepatitis B infection. |
| Papatheodoridis et al. [6] | 2013 | Positive| Long-term ETV treatment may reduce the incidence of HCC in HBV-infected patients. The treatment effect was greater in patients at high risk of HCC. |
| Chiu et al. [21] | 2017 | Positive| Four-year ETV treatment significantly reduces the risk of HCC, cirrhotic events and mortality in patients with CHB-related cirrhosis. |
| Su et al. [29] | 2016 | Positive| Four-year ETV treatment significantly reduces the risk of HCC, cirrhotic events and mortality in patients with CHB-related cirrhosis. |
| Wong et al. [26] | 2013 | Suspected| Entecavir therapy reduces the risk of hepatic events, HCC, liver-related, and all-cause mortality in CHB patients, particularly in those with compensated cirrhosis or older age especially ≥50 years, lower platelets, and liver stiffness ≥12 kPa. |

**Table 4. Approaches to solve the controversy:** Comparisons should be conducted between the incidence of HCC in ETV- or TDF-treated and untreated HBV patients (control group) using the propensity score matching method adjusted for a number of HCC risk factors.

---
Table 5. Experts’ opinions regarding comparison of ETV, TDF, and TAF on reduction of HCC and approaches to solve these controversies

| Author               | Year | Opinion                                                                 | Superiority or equality |
|----------------------|------|-------------------------------------------------------------------------|--------------------------|
| Choi et al. [24]     | 2019 | Tenofovir treatment was associated with a significantly lower risk of HCC compared with ETV treatment | TDF > ETV               |
| Kim et al. [16]      | 2019 | HCC and death or OLT was not statistically different between the ETV and TDF groups | ETV = TDF               |
| Lee et al. [15]      | 2020 | The clinical outcomes in patients with CHB who received TDF or ETV treatment. There was no difference in the intermediate-term risk of HCC and mortality or LT between the two drugs | TDF = ETV               |
| Ha et al. [61]       | 2020 | TDF was associated with lower HCC (HR 0.31, 95% CI, 0.12–0.79; \( p = 0.014 \)); however, statistical significance was not reached | ETV = TDF               |
| Choi et al. [10]     | 2021 | Among patients who underwent curative hepatectomy for HBV-related HCC, TDF therapy was associated with a significantly lower risk of HCC recurrence and better overall patient survival compared with ETV therapy | TDF > ETV               |
| Lee et al. [48]      | 2021 | ETV- and TAF-treated CHB patients have similar risk of developing HCC | ETV = TAF               |
| Zhang et al. [12]    | 2019 | There is a better effect of tenofovir in reducing HCC incidence than ETV, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients | TDF > ETV               |
| Yip et al. [11]      | 2020 | TDF was associated with a lower risk of HCC than treatment with ETV | TDF > ETV               |
| Hsu et al. [14]      | 2020 | TDF and ETV did not significantly differ in the prevention of HCC in patients with CHB | TDF = ETV               |
| Tseng et al. [71]    | 2020 | No significant difference was detected between TDF and ETV in their association with incident HCC | TDF = ETV               |
| Cheung et al. [70]   | 2020 | TDF was associated with a lower HCC risk compared with ETV among patients with CHB, particularly cirrhotic patients | TDF > ETV               |
| Papatheodoridis et al. [72] | 2020 | In Caucasian patients with CHB, with or without cirrhosis, long-term ETV or TDF monotherapy is associated with similar HCC risk | ETV = TDF               |
| Su et al. [73]       | 2021 | No difference in the risk of HCC between patients with CHB treated with ETV versus TDF | ETV = TDF               |

Approach to solve the controversy: further clinical studies or trials with a larger number of patients and longer follow-up are needed to resolve these controversial issues and to reach a consensus.
0.85, \( p < 0.001 \); Table 3) [70]. Taiwan and Asia-Pacific study showed no association between TDF (\( n = 700 \)) and ETV (\( n = 4,837 \)) regimens with HCC risk in a multivariable-adjusted analysis (HR 0.89, 95% CI: 0.41–1.92, \( p = 0.77 \); Table 3) [14].

Another Taiwan and Asia-Pacific study reported that the risk of HCC with TDF (16,266) and ETV (19,702) treatment was similar (primary outcome, TDF: 3.39%/5Y, ETV: 3.44%/5Y; adjusted HR 0.88, 95% CI: 0.73–1.07; \( p = 0.20 \)) by analysis of 14 comparative studies with covariate adjustment. No significant difference between TDF and ETV in their association with incident HCC was observed [71].

In a total of 3,698 patients (1,574 under TDF therapy, and 2,124 under ETV therapy) in China, TDF was more efficacious than ETV in mitigating the HCC incidence (rate ratio [RR-HR combined with incidence rate ratios] 0.66, 95% CI: 0.49–0.89, \( p = 0.008 \); Table 3), indicating that TDF should be used more widely in treating CHB patients [12].

In contrast to the above conflicting Korean and Asian data, European and American studies have concluded that ETV and TDF provide similar efficacy. A European study in 1935 Caucasians with CHB treated with ETV (\( n = 772 \)) and TDF (\( n = 1,163 \)) demonstrated similar HCC risk in the 2 groups (ETV: 1.08% PY, TDF: 1.2% PY, \( p = 0.321 \); Table 3) [72].

In the USA, no difference in the risk of HCC was detected between veteran-affairs patients treated with ETV (\( n = 2,193 \)) and TDF (\( n = 1,094 \)) before and after propensity score matching (HR 1.00, 95% CI: 0.76–1.32; Table 3) [73]. The controversial results can be partly attributed to the arbitrary nature of significance levels, leading to contradictory conclusions from very similar datasets. The use of observational data, however, which is prone to both within- and between-study heterogeneity of patient characteristics, also lends additional uncertainty. The synchronous introduction of ETV and TDF in East Asia, where the majority of these studies were conducted, further complicates analyses, as does the difference in the follow-up times between ETV and TDF cohorts. Researchers conducting meta-analyses in this area must make many methodologic decisions to mitigate bias but are ultimately limited to the methodologies of the included studies. It is therefore important for researchers, as well as the audience of published meta-analyses, to be aware of the quality of observational studies and meta-analyses in terms of patient characteristics, study design, and statistical methodologies [74].

It is important to note that all the studies comparing the risk of HCC between TDF and ETV therapies have indicated one direction favoring TDF or no direction. No high-quality studies have provided evidence favoring ETV over TDF [13]. Further clinical studies or trials with a larger number of patients and longer follow-up are needed to resolve these controversial issues and to reach a consensus.

**Conclusion**

Serum levels of HBV DNA are closely associated with the risk of HCC in CHB patients independent of HBeAg and ALT levels. Treatment with NAs, including ETV, TDF, and TAF, may lower the risk of HCC incidence and recurrence in such patients. Three issues have constrained the resolution of CHB treatment and the obviation of subsequent HCC.

1. The AASLD [7], APASL [8], and EASL [4] guidelines for the management of HBV infection recommend antiviral treatment for HBV with IFN and NAs for the prevention of HCC. Among experts in CHB treatment, however, continuing controversy exists regarding antiviral treatment for the optimal prevention of HCC. A growing evidence from large-scale cohort studies suggests that early initiation of antiviral treatment even with persistently normal ALT levels may be necessary to minimize the risk of HCC.

2. The AASLD, EASL, and APASL guidelines make no recommendations for antiviral treatment in patients in the immune-tolerant phase of CHB, especially patients younger than 30 years of age. Nonetheless, the cutoff level of lower serum HBV DNA levels for the definition of the immune-tolerant phase CHB is not consistent across the guidelines. Even if we have the consensus for the definition of immune-tolerant phase CHB, many patients remain in the gray zone with no treatment recommendations.

3. Whether ETV, TDF, and TAF treatments have different effects on the prevention of HCC is not clear yet. To resolve this issue, we suggest a meta-analysis by using individual patient data from the cohort studies or randomized trials with a larger number of subjects and longer follow-up.

**Acknowledgment**

The authors thank Ms. Mika Matsui for excellent technical assistance.
Conflict of Interest Statement

Young-Suk Lim is an advisory board member of Bayer Healthcare and Gilead Sciences and receives investigator-initiated research funding from Bayer Healthcare and Gilead Sciences. Masatoishi Kudo reports receiving lecture fees from Eisai, Bayer, MSD, Bristol-Myers Squibb, Lilly, and EA Pharma; receiving grants from Gilead Sciences, Taiho, Sumitomo Dainippon Pharma, Takeda, Otsuka, EA Pharma, AbbVie, and Eisai; and having advisory roles at Eisai, Ono, MSD, Bristol-Myers Squibb, and Roche. The other authors have no conflicts of interest to disclose.

Funding Sources

There was no industry involvement in the design, conduct, or analysis of the study. This study was supported by grants from the Patient-Centered Clinical Research Coordinating Center (PACEN; Grant No. HC20C0062) of the National Evidence-based Healthcare Collaborating Agency and the National R&D Program for Cancer Control through the National Cancer Center (Grant No: HA21C0110), funded by the Ministry of Health & Welfare, Republic of Korea. The funding sources had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit the results.

Author Contributions

Kim S.K., Fujii T., Kim S.R., Nakai A., and Hagiwara S. wrote the manuscript; Lim Y.-S. and Kudo M. approved the final version.

References

1 Kim GA, Han SB, Choi GH, Choi JG, Lim YS. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020 Jun;51(11):1169–79.
2 Foreman KJ, Marquez ND, Dolgert A, Fukutake K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018 Nov;392(10159):2052–90.
3 Thomas DL. Global elimination of chronic hepatitis. N Engl J Med. 2019 May;380(21):2041–50.
4 European Association for the Study of the Liver Electronic address easlofice/easloffice. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–98.
5 Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under anti-viral therapy. Clin Mol Hepatol. 2016 Sep;22(3):319–26.
6 Papatheodoridis GV, Idiliman R, Dalekos GN, Buti M, Chihi, van Boemmel P, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017 Nov;66(5):1444–53.
7 Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560–99.
8 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1–98.
9 Kim GA, Lim YS, Han SB, Choi JG, Shim JH, Kim KM, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018 May;67(5):945–52.
10 Choi JG, Jo CY, Lim YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Hepatology. 2021 Feb;73(2):661–73.
11 Yip TCF, Wong VWS, Chan HLY, Tse YK, Lui GCY, Wong GLH. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology. 2020;158(1):215–26.e6.
12 Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta-analysis. BMC Cancer. 2019 May;19(1):511.
13 Choi JG, Lim YS. Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: one direction or no direction. J Hepatol. 2019 Oct;71(4):846–7.
14 Hsu YC, Wong GLH, Chen CH, Peng CY, Yeh ML, Cheung KS, et al. Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B. Am J Gastroenterol. 2020 Feb;115(2):271–80.
15 Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut. 2020 Jul;69(7):1301–8.
16 Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea. J Hepatol. 2019 Sep;71(3):456–64.
17 Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358–80.
18 Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182–236.
19 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul;11(4):317–70.
20 Kim GA, Lim YS, An J, Lee D, Shin JH, Kim KM, et al. HBVAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014 Aug;63(8):1325–32.
21 Choi JG, Han S, Kim N, Lim YS. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology. 2017 Nov;66(5):1454–63.
22 Lim YS, Han SB, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014 Jul;147(1):152–61.
23 Kim GA, Han S, Kim HD, An J, Lim YS. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response. J Viral Hepat. 2017 Nov;24(11):990–7.
HBV Treatment and HCC Controversy and Approaches to Consensus

24 Choi JG, Kim HJ, Lee JY, Cho SH, Ko MJ, Lim YS. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean Nationwide Cohort Study. JAMA Oncol. 2019 Jan;5(1):30–6.

25 Liaw FY, Sung JYF, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct;351(15):1521–31.

26 Wong GLH, Chan HLY, Mak CWH, Lee SKY, Ip ZMY, Lam ATH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013 Nov;58(5):1537–47.

27 Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013 Jul;58(1):80–90.

28 Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014 Jul;147(1):143–51.e5.

29 Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhosis, and mortality in chronic hepatitis B patients. Liver Int. 2016 Dec;36(12):1755–64.

30 Korean Liver Cancer Association. 2018 Korean Liver Cancer Association: National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019 May;13(3):227–99.

31 GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease study 2015. Lancet. 2016;388(10053):1459–544.

32 Wong GLH. Management of chronic hepatitis B patients in immunotolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018 Jun;24(2):108–13.

33 Korean Association for the Study of the Liver KASL. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019 Jun;25(2):93–159.

34 Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan;295(1):65–73.

35 Choi GH, Kim GA, Choi JG, Han SB, Lim YS. High risk of clinical events in untreated HBsAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther. 2019 Jul;50(2):213–26.

36 Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016 Nov;151(5):986–98.e4.

37 Mason WS, Liu C, Aldrich CE, Litwin S, Yeh MM. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J Virol. 2010 Aug;84(16):8308–15.

38 Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009 Dec;286(1):52–9.

39 Marongiu F, Doratiotto S, Montisci S, Pani P, Lacomini E. Liver repopulation and carcinogenesis: two sides of the same coin? Ann J Pathol. 2008 Apr;172(4):857–64.

40 Sivicher V, Salpini R, Battisti A, Colagrossi L, Piermatteo L, Surdo M, et al. GS-17-the integration of Hepatitis B virus into human genome is a common event in the setting of HBsAg negative disease: implications for the treatment and management of CHB. J Hepatol. 2019;70(1):83–4.

41 Buti M, Gane E, Seto WK, Chuang WL, Stepanova T, et al. Tenofovir alafenamide vs tenofovir disoproxil fumarate for chronic hepatitis B in immunotolerant phase with high viral load and no significant ALT elevation. Aliment Pharmacol Ther. 2019 Jul;50(2):213–26.

42 Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016 Nov;151(5):986–98.e4.
61 Ha YJ, Chon YE, Kim MN, Lee JH, Hwang SG. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate. Sci Rep. 2020 Aug;10(1):13537.
62 Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology. 2015 Sep;62(3):694–701.
63 Cho YY, Lee JH, Chang Y, Nam JY, Cho H, Lee DH, et al. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. J Viral Hepat. 2018 Oct;25(10):1161–71.
64 Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol. 2020 Jul;26(3):364–75.
65 Hsu YC, Yip TCF, Ho HY, Wong VWS, Huang YT, El-Serag HB, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018 Aug;69(2):278–85.
66 Laccetti M, Manes G, Uomo G, Lionello M, Rabitti PG, Balzano A. Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Dig Liver Dis. 2000 May;32(4):335–8.
67 Chao X, Qian H, Wang S, Fulte S, Ding WX. Autophagy and liver cancer. Clin Mol Hepatol. 2020 Oct;26(4):606–17.
68 Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, et al. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: results of a single-arm, phase II clinical trial. Clin Mol Hepatol. 2020 Oct;26(4):506–15.
69 Kim BG, Park NH, Lee SB, Jeon S, Park JH, Jung SW, et al. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B. Liver Int. 2018 Dec;38(12):2269–76.
70 Cheung KS, Mak LY, Liu SH, Cheng HM, Seto WK, Yuen MF, et al. Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2020 Oct;11(10):e00236.
71 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1039–52.
72 Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol. 2020 Nov;73(5):1037–45.
73 Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut. 2021;70(2):370–8.
74 Choi WM, Yip TCF, Lim YS, Wong GLH, Kim WR. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol. 2022 Jan;76(1):186–94.